1051 related articles for article (PubMed ID: 18032762)
1. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Kampfenkel T; Liu W; Wang J; Kosh M; Tran N; Carson R; Sonneveld P
Lancet Haematol; 2023 Oct; 10(10):e813-e824. PubMed ID: 37793772
[TBL] [Abstract][Full Text] [Related]
3. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.
Paludo J; Mikhael JR; LaPlant BR; Halvorson AE; Kumar S; Gertz MA; Hayman SR; Buadi FK; Dispenzieri A; Lust JA; Kapoor P; Leung N; Russell SJ; Dingli D; Go RS; Lin Y; Gonsalves WI; Fonseca R; Bergsagel PL; Roy V; Sher T; Chanan-Khan AA; Ailawadhi S; Stewart AK; Reeder CB; Richardson PG; Rajkumar SV; Lacy MQ
Blood; 2017 Sep; 130(10):1198-1204. PubMed ID: 28684537
[TBL] [Abstract][Full Text] [Related]
4. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Kumar S; Moreau P; Hari P; Mateos MV; Ludwig H; Shustik C; Masszi T; Spencer A; Hájek R; Romeril K; Avivi I; Liberati AM; Minnema MC; Einsele H; Lonial S; Berg D; Lin J; Gupta N; Esseltine DL; Richardson PG
Br J Haematol; 2017 Aug; 178(4):571-582. PubMed ID: 28485007
[TBL] [Abstract][Full Text] [Related]
5. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.
Xia Z; Leng Y; Fang B; Liang Y; Li W; Fu C; Yang L; Ke X; Jiang H; Weng J; Liu L; Zhao Y; Zhang X; Huang Z; Liu A; Shi Q; Gao Y; Chen X; Pan L; Cai Z; Wang Z; Wang Y; Fan Y; Hou M; Ma Y; Hu J; Liu J; Zhou J; Zhang X; Meng H; Lu X; Li F; Ren H; Huang B; Shao Z; Zhou H; Hu Y; Yang S; Zheng X; Wei P; Pang H; Yu W; Liu Y; Gao S; Yan L; Ma Y; Jing H; Du J; Ling W; Zhang J; Sui W; Wang F; Li X; Chen W
BMC Cancer; 2023 Oct; 23(1):980. PubMed ID: 37838670
[TBL] [Abstract][Full Text] [Related]
6. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Lu J; Lee JH; Huang SY; Qiu L; Lee JJ; Liu T; Yoon SS; Kim K; Shen ZX; Eom HS; Chen WM; Min CK; Kim HJ; Lee JO; Kwak JY; Yiu W; Chen G; Ervin-Haynes A; Hulin C; Facon T
Br J Haematol; 2017 Mar; 176(5):743-749. PubMed ID: 28106903
[TBL] [Abstract][Full Text] [Related]
7. Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Lee SE; Lim JY; Ryu DB; Kim TW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim M; Min CK
Cancer Immunol Immunother; 2016 Aug; 65(8):983-94. PubMed ID: 27342591
[TBL] [Abstract][Full Text] [Related]
8. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Richardson PG; Oriol A; Larocca A; Bladé J; Cavo M; Rodriguez-Otero P; Leleu X; Nadeem O; Hiemenz JW; Hassoun H; Touzeau C; Alegre A; Paner A; Maisel C; Mazumder A; Raptis A; Moreb JS; Anderson KC; Laubach JP; Thuresson S; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Mateos MV;
J Clin Oncol; 2021 Mar; 39(7):757-767. PubMed ID: 33296242
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Palumbo A; Obreja M; Aggarwal S; Moreau P
Br J Haematol; 2017 May; 177(3):404-413. PubMed ID: 28211560
[TBL] [Abstract][Full Text] [Related]
10. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Dimopoulos MA; Lonial S; White D; Moreau P; Palumbo A; San-Miguel J; Shpilberg O; Anderson K; Grosicki S; Spicka I; Walter-Croneck A; Magen H; Mateos MV; Belch A; Reece D; Beksac M; Bleickardt E; Poulart V; Sheng J; Sy O; Katz J; Singhal A; Richardson P
Br J Haematol; 2017 Sep; 178(6):896-905. PubMed ID: 28677826
[TBL] [Abstract][Full Text] [Related]
11. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Richardson PG; Trudel S; Popat R; Mateos MV; Vangsted AJ; Ramasamy K; Martinez-Lopez J; Quach H; Orlowski RZ; Arnao M; Lonial S; Karanes C; Pawlyn C; Kim K; Oriol A; Berdeja JG; Rodríguez Otero P; Casas-Avilés I; Spirli A; Poon J; Li S; Gong J; Wong L; Lamba M; Pierce DW; Amatangelo M; Peluso T; Maciag P; Katz J; Pourdehnad M; Bahlis NJ;
N Engl J Med; 2023 Sep; 389(11):1009-1022. PubMed ID: 37646702
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
Zonder JA; Crowley J; Hussein MA; Bolejack V; Moore DF; Whittenberger BF; Abidi MH; Durie BG; Barlogie B
Blood; 2010 Dec; 116(26):5838-41. PubMed ID: 20876454
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Dimopoulos MA; Swern AS; Li JS; Hussein M; Weiss L; Nagarwala Y; Baz R
Blood Cancer J; 2014 Nov; 4(11):e257. PubMed ID: 25382609
[TBL] [Abstract][Full Text] [Related]
14. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.
Dimopoulos MA; Leleu X; Palumbo A; Moreau P; Delforge M; Cavo M; Ludwig H; Morgan GJ; Davies FE; Sonneveld P; Schey SA; Zweegman S; Hansson M; Weisel K; Mateos MV; Facon T; Miguel JF
Leukemia; 2014 Aug; 28(8):1573-85. PubMed ID: 24496300
[TBL] [Abstract][Full Text] [Related]
15. c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
Di Bacco A; Bahlis NJ; Munshi NC; Avet-Loiseau H; Masszi T; Viterbo L; Pour L; Ganly P; Cavo M; Langer C; Kumar SK; Rajkumar SV; Keats JJ; Berg D; Lin J; Li B; Badola S; Shen L; Zhang J; Esseltine DL; Luptakova K; van de Velde H; Richardson PG; Moreau P
Eur J Haematol; 2020 Jul; 105(1):35-46. PubMed ID: 32145111
[TBL] [Abstract][Full Text] [Related]
16. A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.
Maly JJ; Christian BA; Zhu X; Wei L; Sexton JL; Jaglowski SM; Devine SM; Fehniger TA; Wagner-Johnston ND; Phelps MA; Bartlett NL; Blum KA
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):347-353. PubMed ID: 28622959
[TBL] [Abstract][Full Text] [Related]
17. Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.
Cella D; McKendrick J; Kudlac A; Palumbo A; Oukessou A; Vij R; Zyczynski T; Davis C
Ann Hematol; 2018 Dec; 97(12):2455-2463. PubMed ID: 30178193
[TBL] [Abstract][Full Text] [Related]
18. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).
Hitz F; Kraus M; Pabst T; Hess D; Besse L; Silzle T; Novak U; Seipel K; Rondeau S; Stüdeli S; Vilei SB; Samaras P; Mey U; Driessen C;
Blood Cancer J; 2019 Aug; 9(9):70. PubMed ID: 31455773
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of scleromyxedema with daratumumab, lenalidomide and dexamethasone in a patient with multiple myeloma.
Bettolini L; Bighetti S; Maione V; Ghini I; Segala D; Calzavara-Pinton P
Australas J Dermatol; 2024 Jun; 65(4):e104-e107. PubMed ID: 38326991
[No Abstract] [Full Text] [Related]
20. Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.
Kubicki T; Jamroziak K; Robak P; Czyż J; Tyczyńska A; Druzd-Sitek A; Giannopoulos K; Wróbel T; Nowicki A; Szczepaniak T; Łojko-Dankowska A; Matuszak M; Gil L; Puła B; Szukalski Ł; Końska A; Zaucha JM; Walewski J; Mikulski D; Czabak O; Robak T; Kruk-Kwapisz D; Derman BA; Major A; Jakubowiak AJ; Dytfeld D
Pol Arch Intern Med; 2024 May; 134(5):. PubMed ID: 38747414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
